Tag: Stereotactic radiosurgery

Posted on

The role of salvage stereotactic radiosurgery for tumor progression following incomplete microsurgical resection of vestibular schwannoma

J Neurosurg 144:1403–1409, 2026

This clinical study evaluates salvage stereotactic radiosurgery (SRS) for vestibular schwannoma (VS) that progresses after incomplete microsurgical resection, reporting long-term tumor control, freedom from additional treatment (FFAT), and complication rates in a 64-patient cohort. Key outcomes include 10- and 15-year tumor control of 87.5% and 84.4%, and FFAT of 95.3% and 92.2%, respectively.

The methods describe retrospective selection, radiosurgical dosimetry (median margin 12.5 Gy), imaging and follow-up protocols, and statistical analyses using Kaplan–Meier and Cox models; no factors significantly predicted control or FFAT, and common complications included trigeminal neuropathy and hearing worsening.

Objective Assess safety/efficacy of salvage stereotactic radiosurgery (SRS) for vestibular schwannoma (VS) that progresses after incomplete microsurgical resection, including factors affecting tumor control and freedom from additional treatment (FFAT).

Cohort Retrospective series of 64 adults treated with salvage SRS for post-resection tumor progression; median age 51.5 years and 46.9% male.

Treatment parameters Median marginal dose 12.5 Gy (median isodose 50%); median tumor volume 1.6 cm³; median time from surgery to salvage SRS 38.8 months.

Long-term control Tumor control rates after salvage SRS were 87.5% at 10 years and 84.4% at 15 years.

Durability (FFAT) FFAT rates were 95.3% at 10 years and 92.2% at 15 years, indicating most patients avoided further intervention long term.

Predictors No evaluated factors (e.g., Koos grade, age/sex, cranial nerve neuropathies, marginal dose, extent of resection, tumor volume) were significantly associated with tumor control or FFAT in Cox modeling.

Complications Most common post-SRS issue was worsening/new trigeminal neuropathy (15.6% total); hearing worsened in 14.1% (Gardner-Robertson class), and facial nerve function worsened in 4.7% (House-Brackmann).

Conclusion Salvage SRS is a safe and effective long-term strategy for VS tumor progression after incomplete resection, supporting continued monitoring and consideration of SRS once progression is documented.

Posted on

Stereotactic Radiosurgery Versus Observation in Small- and Medium-Sized Vestibular Schwannoma Patients With Normal Hearing: A Retrospective International Multicenter Study

Neurosurgery 98:887–894, 2026

This multicenter retrospective study compares stereotactic radiosurgery (SRS) with observation (OBS) for small-to-medium vestibular schwannomas (Koos I–II) in patients presenting with normal (AAO‑HNS class A) hearing. Propensity-score–matched cohorts (57 SRS, 57 OBS) were analyzed for serviceable hearing preservation (SHP), tumor control (TC), and cranial nerve outcomes over median follow-ups of 49 and 37 months.

Results show SRS achieved markedly superior tumor control (≈98% at 5–10 years) while producing noninferior hearing outcomes versus observation (5‑year SHP: SRS 76.2% vs OBS 56.1%; difference not statistically significant). The authors conclude SRS is preferable for TC without compromising hearing, emphasizing individualized decision-making given study limitations.

Clinical question Comparison of stereotactic radiosurgery (SRS) vs observation (OBS) for small/medium Koos I–II vestibular schwannomas in patients with AAO-HNS class A (normal) hearing at presentation, focusing on hearing preservation and tumor control

Design Retrospective international multicenter study with propensity score matching (age, sex, tumor volume, PTA, SDS) yielding 57 SRS vs 57 OBS matched patients

Serviceable hearing preservation No statistically significant difference in long-term serviceable hearing preservation between SRS and OBS in the matched analysis (log-rank P = .17), despite numerically higher SRS rates

Hearing rates over time Matched-cohort 5-/9-year serviceable hearing preservation: SRS 76.2% / 42.4% vs OBS 56.1% / 16.8%

Class A hearing Class A preservation was similar: 57.9% (SRS) vs 52.6% (OBS) (P = .70)

Tumor control SRS achieved markedly superior tumor control (log-rank P < .0001); 5-/10-year tumor control: SRS 97.9% / 97.9% vs OBS 40.9% / 15.1%

Other clinical outcomes No significant matched-cohort differences in cranial nerve deficits, vestibulopathy, or composite CN/tinnitus worsening; tinnitus worsening trended higher with OBS (21.1% vs 8.8%) but was not significant (P = .066)

Overall conclusion SRS provided noninferior hearing outcomes while being significantly better for tumor control, supporting SRS as a favored option while still emphasizing individualized decision-making

Posted on

Long-term tumor control after Gamma Knife radiosurgery for sporadic vestibular schwannoma

J Neurosurg 144:965–971, 2026

This clinical study evaluates long-term tumor control after single-fraction Gamma Knife stereotactic radiosurgery (SRS) for sporadic vestibular schwannoma in 749 adults treated from 2000–2022, reporting Kaplan–Meier control rates of 100%, 98%, 96%, 92%, and 91% at 1, 3, 5, 10, and 15 years respectively. Patient demographics, SRS dosing, and complication rates—including low persistent facial paresis—are summarized with statistical analysis and clear definitions for growth, pseudoprogression, and salvage.

The authors detail three post-SRS tumor behavior patterns, finding 13% pseudoprogression (mostly within 5 years) and 42 salvage treatments (median 3.7 years), and conclude that SRS offers durable control while emphasizing the need for prolonged surveillance and nuanced clinical decision-making about retreatment.

Objective Assess long-term efficacy of single-fraction stereotactic radiosurgery (SRS) as primary treatment for adult, treatment-naïve sporadic vestibular schwannoma (Gamma Knife), treated from 2000–2022.

Cohort 749 adults included; 76% had tumors extending into the cerebellopontine angle (CPA) at SRS; median age 62; 50% women; 99% had House-Brackmann (HB) grade I facial nerve function at SRS.

Long-term tumor control Tumor control after SRS remained high: 100% (1 yr), 98% (3 yr), 96% (5 yr), 92% (10 yr), and 91% (15 yr).

Radiosurgical failure/salvage 42 patients required salvage (35 microsurgery, 7 repeat SRS), median 3.7 years post-SRS; 3 salvage treatments occurred >10 years after SRS, indicating late failures can occur.

Risk factors Age, macrocystic tumor presence, and treated tumor volume were not significantly associated with risk of salvage in univariable analysis.

Post-SRS tumor patterns Three post-SRS behaviors were observed: (1) stability/shrinkage, (2) pseudoprogression (growth then stability/shrinkage), and (3) continued growth without stability at last follow-up.

Pseudoprogression timing 13% experienced pseudoprogression; all but 4 showed it by year 5 post-SRS, though some initial growth occurred later (e.g., 5.1–8.6 years) with subsequent stability on follow-up imaging.

Conclusion/implication SRS provides durable control through 15 years for most patients (91%), but ongoing long-term surveillance is needed because failures may occur even beyond 10 years and pseudoprogression can be seen out to ≥5 years.

Posted on

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Surgical Resection for the Treatment of Patients With Vestibular Schwannomas: Update

Neurosurgery 98:272–277, 2026

These updated Congress of Neurological Surgeons guidelines review surgical management of sporadic vestibular schwannomas using literature from 2015–2022, reaffirming many prior recommendations and highlighting persistent evidence gaps. Key recommendations address approach selection (middle fossa, retrosigmoid, translabyrinthine), hearing-preservation surgery options, and counseling patients about outcomes after prior stereotactic radiosurgery.

The document details systematic review methods, inclusion criteria, and evidence grading, noting most data are class III and insufficient to prove superiority of specific surgical approaches for many questions. It emphasizes individualized treatment decisions, need for multicenter registries or trials, and future research priorities to resolve unanswered clinical issues.

Surgical Approach Selection: No surgical approach (middle fossa, retrosigmoid, or translabyrinthine) has proven superiority for facial nerve preservation or gross total resection in sporadic vestibular schwannoma; choice depends on individual patient factors and tumor characteristics.

Hearing Preservation: Hearing preservation surgery via middle fossa or retrosigmoid approach may be considered for patients with good preoperative hearing as an alternative to observation, but evidence for long-term superiority is limited.

Subtotal Resection and Radiosurgery: Subtotal resection followed by stereotactic radiosurgery does not have sufficient evidence to support better facial nerve or hearing outcomes compared to complete resection.

Microsurgery After SRS: Patients undergoing microsurgical resection after prior stereotactic radiosurgery should be counseled about increased risk of subtotal resection and worse facial nerve function.

Trigeminal Neuralgia: Surgical resection may provide better relief of trigeminal neuralgia symptoms compared to stereotactic radiosurgery in patients with sporadic vestibular schwannoma.

Balance and Observation: There is insufficient evidence to support surgery or radiosurgery for improving preoperative balance problems, and no clear evidence that surgery should be primary treatment for small tumors eligible for observation.

Evidence Quality: All reviewed evidence is class III (retrospective series, flawed controls), with significant potential for bias and limitations in drawing strong conclusions.

Future Directions: Improved data from multicenter registries or randomized trials are needed to clarify optimal management, as current recommendations reflect standard practice but lack high-level evidence for many questions.

Posted on

Single-Fraction Stereotactic Radiosurgery as Primary Management of Sporadic Meningiomas: A 25-Year Cohort Study

Neurosurgery 97:1267–1274, 2025

This study reports long-term outcomes of single‑fraction Gamma Knife stereotactic radiosurgery (SRS) as primary treatment for 653 sporadic intracranial meningiomas in 616 patients over a 25‑year period. With median margin dose 15 Gy and median imaging follow-up 6.3 years, progression‑free survival was excellent (99.8% at 5 years, 99.0% at 10 years), and raw tumor control reached 98.6%.

Treatment‑related neurological sequelae were uncommon (1.8% permanent/intervention), though larger tumor volume, higher V12, and greater number of isocenters increased complication risk. The authors conclude single‑fraction SRS at studied doses offers high long‑term control for small‑to‑medium sporadic meningiomas, emphasizing careful patient selection.

Stereotactic Radiosurgery (SRS) Effectiveness: Single-fraction SRS is highly effective as a primary treatment for sporadic, small- to medium-volume intracranial meningiomas, achieving a 99% tumor control rate at 10 years and 93% at 15 years progression-free survival (PFS).

Low Permanent Morbidity: The risk of permanent treatment-related neurological complications is low (1.8%), with most side effects being temporary or minor.

Key Predictors of Outcome: Larger tumor volume is the main predictor of both tumor progression and treatment-related complications, emphasizing the importance of patient selection for SRS.

Radiosurgical Parameters: Increased number of isocenters, higher 12-Gy volume (V12), larger tumor volume, and lower maximal dose are associated with higher risk of treatment-related complications.

Comparison to Observation: SRS provides superior tumor control compared to observation in patients with incidentally discovered, asymptomatic meningiomas, with similar rates of new neurological deficits.

Radiation Dose Recommendations: A median margin dose of 13–15 Gy balances long-term tumor control and risk of complications; doses below 12 Gy may increase recurrence risk, while higher doses increase morbidity.

Biological Effective Dose (BED): In this cohort, higher BED was not predictive of improved PFS, likely due to the already high dosing protocol; however, other studies suggest BED can be a useful predictor when a wider dose range is used.

Limitations: The study is retrospective and single-institution, with potential selection bias and incomplete follow-up; findings may not generalize to syndromic or radiation-induced meningiomas.

 

Posted on

Detailed Analysis of Late Adverse Effects of Stereotactic Radiosurgery for Dural Arteriovenous Fistulas

Neurosurgery 97:1368–1376, 2025

This single-center retrospective study evaluates long-term late radiation-induced complications (LRICs) after stereotactic radiosurgery (SRS) for dural arteriovenous fistulas (DAVFs) in 30 patients over a median 99-month follow-up, reporting obliteration rates, post-SRS T2 signal changes, and incidence of chronic encapsulated hematoma (CEH). Findings show high DAVF obliteration (79.6% at 5 years) with rare but notable LRICs (11.1% at 10 years), and an association between post-SRS signal changes and CEH occurrence.

The report details radiosurgical techniques, diagnostic criteria, case courses of two asymptomatic CEHs managed conservatively, and discusses pathophysiology linking radiation, VEGF-mediated permeability, and lesion expansion. The authors recommend prolonged imaging surveillance, heightened monitoring for patients with post-SRS T2 changes, and call for larger multicenter studies to refine predictive models and management strategies.

Posted on

Gamma Knife radiosurgery for relapsing trigeminal neuralgia following microvascular decompression

J Neurosurg 142:1247–1255, 2025

Salvage Gamma Knife radiosurgery (GKRS) offers effective, noninvasive treatment for relapsing trigeminal neuralgia after microvascular decompression, with a favorable complications profile. Patients with facial numbness and better initial pain responses may experience more durable pain relief following salvage GKRS.

• Gamma Knife radiosurgery (GKRS) is explored as a treatment for relapsing trigeminal neuralgia (TN) following microvascular decompression (MVD).

• The study aimed to assess the response rate, complications, and predictors of pain relapse for salvage GKRS after MVD.

• 83.1% of patients experienced initial pain relief after salvage GKRS, with a median time to relapse of 1.75 years.

• Facial numbness post-GKRS decreased pain relapse risk, while a worse initial pain response increased it.

• Radiofrequency ablation (RFA) prior to MVD reduced the likelihood of an initial response to GKRS.

• Salvage GKRS is presented as an effective, noninvasive option for recurring TN after MVD, with a favorable complications profile compared to salvage MVD.

• The study acknowledges limitations, including potential selection bias and small sample size, and suggests further research with larger cohorts

Posted on

Predictors of trigeminal neuropathy in patients receiving Gamma Knife stereotactic radiosurgery for vestibular schwannoma

J Neurosurg 142:1134–1140, 2025

The study investigates predictors of trigeminal neuropathy (Tn) in patients receiving Gamma Knife stereotactic radiosurgery for vestibular schwannoma. It identifies the volume of cranial nerve V receiving ≥11 Gy as a significant factor in Tn development, suggesting it be included in dosimetric planning to minimize risk.

• Objective: Validate predictors of trigeminal neuropathy (Tn) in patients receiving stereotactic radiosurgery (SRS) for vestibular schwannoma (VS).

• Methodology: Study included 204 patients treated with SRS, excluding those with pre-existing Tn symptoms or less than 2 years of follow-up.

• Key Finding: The volume of cranial nerve (CN) V receiving ≥ 11 Gy is the only significant predictor of Tn development post-SRS.

• Results: 11.3% of patients developed Tn, with 7.8% experiencing permanent symptoms.

• Statistical Analysis: Maximum dose to CN V was significant in univariate analysis but not in multivariate analysis.

• Tumor Compression: Not significantly correlated with Tn development.

• Clinical Implication: Dosimetric planning should account for CN V volume receiving ≥ 11 Gy to minimize Tn risk.

• Recommendation: Early treatment advised to maintain gap between VS and CN V, reducing Tn risk.

Posted on

Gamma Knife Radiosurgery for Hypothalamic Hamartoma: A Multi-Institutional Retrospective Study on Safety, Efficacy, and Complication Profile

Neurosurgery 96:426–437, 2025

• Study Overview:

•Retrospective multicentric study on 39 patients with hypothalamic hamartomas (HH).

•Mean age of patients was 16 years, with a range from 6 months to 53 years.

•Ethical clearance obtained for data sharing from participating centers.

• Treatment Details:

•Gamma Knife Radiosurgery (GKRS) used with a median margin dose of 16 Gy.

•Target volume median was 0.55 cc, ranging from 0.1 to 10.00 cc.

•Majority of patients received ≥16 Gy targeting complete HH.

• Seizure Outcomes:

•55.2% achieved good seizure control (Engel I/II).

•44.8% were in Engel III/IV status.

•No significant difference in seizure outcomes based on prescribed dose.

• Complications and Side Effects:

•Two patients developed new onset hormonal deficiency.

•No new onset visual deterioration observed.

•Eight patients experienced a transient increase in seizures.

• Endocrinological Impact:

•17.9% of patients presented with both precocious puberty (PP) and epilepsy.

•No significant change in endocrinological profile post-radiosurgery.

• Follow-up and Long-term Effects:

•Median follow-up duration was 5 years.

•Regression in hamartoma volume observed in 28% of patients.

•Long-term follow-up essential for observing significant outcomes

Posted on

Multistaged Stereotactic Radiosurgery for Complex Large Lobar Arteriovenous Malformations

Neurosurgery 96:223–232, 2025

Although stereotactic radiosurgery (SRS) has well defined outcomes in the management of smaller-volume arteriovenous malformations (AVM), this report evaluates the outcomes when SRS is used for large-volume (≥10 cc) lobar AVMs.

METHODS: Between 1990 and 2022, a cohort of 1325 patients underwent Leksell Gamma Knife SRS for brain AVMs. Among these, 40 patients (25 women; median age: 37 years) with large lobar AVMs underwent volume-staged SRS followed by additional SRS procedures if needed (2-5 procedures). The patients presented with diverse AVM locations and Spetzler-Martin Grades. Before SRS, 16 patients underwent a total of 43 embolization procedures.

RESULTS: Over a median follow-up of 73 months, 20 patients achieved AVM obliteration. The 3, 5, and 10-year obliteration rates were 9.3%, 15.3%, and 53.3%, respectively. During the latency interval between the first SRS procedure and the last follow-up, 11 patients had intracerebral hemorrhages (ICH) and 6 developed new neurological deficits unrelated to ICH. The postoperative hemorrhage risk after the first SRS was 13.8% at 3 years, 16.6% at 5 years, and 36.2% at 10 years. No hemorrhagic event was documented after confirmed obliteration. Compared with the modified Rankin Scale (mRS) scores before SRS, the mRS improved or remained stable in 28 patients. Nine patients died during the observation interval. Five were related to ICH.

CONCLUSION: These outcomes underscore both the potential effectiveness and the limitations of multistage SRS procedures for complex high-risk large volume AVMs in critical brain lobar locations. Most patients retained either stable or improved long-term mRS scores. During the latency interval from the first SRS until obliteration, achieved after two or more procedures, the risk of hemorrhage and treatment-related complications persists.

Posted on

Anterior selective targeting for radiosurgical treatment of trigeminal neuralgia: a cohort study

Acta Neurochirurgica (2024) 166:482

Before commonly used targets such as the Retrogasserian Zone (RGZ) and the Root Entry Zone (REZ) were adopted for the radiosurgical treatment of trigeminal neuralgia (TN), a more anterior target involving the Gasserian ganglion was used. Thanks to advancements in imaging technology, it is now possible to identify and target separate nerve divisions in Meckel’s Cave as desired. Although this approach has been mentioned previously, no clinical study has investigated it until now. This study aims to fill this gap in the literature.

Methods Trigeminal neuralgia patients who received radiosurgical treatment between February 2019 and June 2022 in a single centre were included in the study. Pain relief, medication dependency and side effect profiles of the investigated anterior selective target (AST) were compared to those of the classical targets at 1 week, 1–3-6 months, and 1 year.

Results A total of 66 patients were included in the study. Effectiveness, safety and application convenience parameters were compared between; the REZ (n = 21), RGZ (n = 20) and AST (n = 25) groups. All groups showed significant improvement in pain with similar results to each other. AST treatments were performed in significantly shorter beam-on-times and with significantly lower brainstem doses.

Conclusions The investigated AST showed comparable results to the classical targets without any indication of superiority or inferiority in terms of efficacy and safety in this preliminary investigation. As no blocks were needed to protect the brainstem with this method, it can be used for select patients as needed and could even be investigated in larger studies as an alternative approach.

Posted on

Preoperative stereotactic radiosurgery for cerebral metastases: safe, effective, and decreases steroid dependency

J Neurosurg 141:1332–1342, 2024

Preoperative stereotactic radiosurgery (SRS) is emerging as a viable alternative to standard postoperative SRS. Studies have suggested that preoperative SRS provides comparable tumor control and overall survival (OS) and may reduce the incidence of leptomeningeal disease (LMD) and adverse radiation effects (AREs). It is unknown, however, if preoperative SRS remains effective in cohorts including large brain metastases (> 14 cm 3 ) or if preoperative SRS affects steroid taper/immunotherapy. Here, the authors report the results of a phase 2 single-arm trial assessing a prospectively acquired series of 26 patients who underwent preoperative SRS, without a volumetric cutoff, compared with a propensity score–matched concurrent cohort of 30 patients who underwent postoperative SRS to address these salient questions.

METHODS Demographics, oncological history, surgical details, and outcomes were collected from the medical records. Coprimary endpoints were local tumor control (LTC) and a composite outcome of LTC, ARE, and LMD. Additional outcomes were OS, steroid taper details, and immunotherapy resumption. For survival analyses, cohorts were propensity score matched.

RESULTS Preoperative and postoperative SRS patients were comparable in terms of age, sex, Karnofsky Performance Status score, oncological history, and operative details. Gross tumor volume (GTV) was significantly higher in the preoperative group (median 12.2 vs 5.3 cm 3 , p < 0.001). One-year LTC (preoperative SRS: 77.2% vs postoperative SRS: 82.5%, p = 0.61) and composite outcome (68.3% vs 72.7%, p = 0.38) were not significantly different between the groups. In multivariable analysis, preoperative SRS did not have a significant effect on LTC (HR 1.57 [95% CI 0.38–6.49], p = 0.536) or the composite outcome (HR 1.18 [95% CI 0.38–3.72], p = 0.771), although the confidence intervals were large. The median OS (preoperative SRS: 17.0 vs postoperative SRS: 14.0 months, p = 0.61) was not significantly different. Rates of LMD were nonsignificantly lower in the preoperative SRS group (3.8% vs 16.7%, p = 0.200). Greater GTV volume was associated with prolonged (> 10 days) steroid taper (OR 1.24 [95% CI 1.04–1.55], p = 0.032). However, in multivariable analysis, preoperative SRS markedly reduced the steroid taper length (OR 0.13 [95% CI 0.02–0.61], p = 0.016). Time to immunotherapy was shorter in the preoperative SRS group (36 [IQR 26, 76] vs OR 228 [IQR 129, 436] days, p = 0.02).

CONCLUSIONS Compared with postoperative SRS, preoperative SRS is a safe and effective strategy in the management of cerebral metastases of all sizes and provides comparable tumor control without increased adverse effects. Notably, preoperative SRS enabled rapid steroid taper, even in larger tumors. Future studies should specifically examine the interaction of preoperative SRS with steroid usage and resumption of systemic therapies and the subsequent effects on systemic progression and OS.

Clinical trial registration no.: NCT02514915 (ClinicalTrials.gov)

Posted on

Benefits of stereotactic radiosurgical anterior capsulotomy for obsessive-compulsive disorder: a meta-analysis

J Neurosurg 141:394–405, 2024

Anterior capsulotomy (AC) is a therapeutic option for patients with severe, treatment-resistant obsessive-compulsive disorder (OCD). The procedure can be performed via multiple techniques, with stereotactic radiosurgery (SRS) gaining popularity because of its minimally invasive nature. The risk-benefit profile of AC performed specifically with SRS has not been well characterized. Therefore, the primary objective of this study was to characterize outcomes following stereotactic radiosurgical AC in OCD patients.

METHODS Studies assessing mean Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores before and after stereotactic radiosurgical AC for OCD were included in this analysis. Inverse-variance fixed-effect modeling was used for pooling, and random-effects estimate of the ratio of means and standard mean differences were calculated at 6 months, 12 months, and the last follow-up for Y-BOCS scores, as well as the last follow-up for the Beck Depression Inventory (BDI)/BDI-II scores. A generalized linear mixed model was used to generate fixed- and random-effects models for categorical outcomes. Univariate random-effects meta-regression was used to evaluate associations between postoperative Y-BOCS scores and study covariates. Adverse events were summed across studies. Publication bias was assessed with Begg’s test.

RESULTS Eleven studies with 180 patients were eligible for inclusion. The mean Y-BOCS score decreased from 33.28 to 17.45 at the last-follow up (p < 0.001). Sixty percent of patients were classified as responders and 10% as partial responders, 18% experienced remission, and 4% had worsened Y-BOCS scores. The degree of improvement in the Y-BOCS score correlated with time since surgery (p = 0.046). In the random-effects model, the mean BDI at the last follow-up was not significantly different from that preoperatively. However, in an analysis performed with available paired pre- and postoperative BDI/BDI-II scores, there was significant improvement in the BDI/BDI-II scores postoperatively. Adverse events numbered 235, with headaches, weight change, mood changes, worsened depression/anxiety, and apathy occurring most commonly.

CONCLUSIONS Stereotactic radiosurgical AC is an effective technique for treating OCD. Its efficacy is similar to that of AC performed via other lesioning techniques.

Posted on

The relevance of biologically effective dose for pain relief and sensory dysfunction after Gamma Knife radiosurgery for trigeminal neuralgia: an 871-patient multicenter study

J Neurosurg 141:461–473, 2024

Recent studies have suggested that biologically effective dose (BED) is an important correlate of pain relief and sensory dysfunction after Gamma Knife radiosurgery (GKRS) for trigeminal neuralgia (TN). The goal of this study was to determine if BED is superior to prescription dose in predicting outcomes in TN patients undergoing GKRS as a first procedure.

METHODS This was a retrospective study of 871 patients with type 1 TN from 13 GKRS centers. Patient demographics, pain characteristics, treatment parameters, and outcomes were reviewed. BED was compared with prescription dose and other dosimetric factors for their predictive value.

RESULTS The median age of the patients was 68 years, and 60% were female. Nearly 70% of patients experienced pain in the V2 and/or V3 dermatomes, predominantly on the right side (60%). Most patients had modified BNI Pain Intensity Scale grade IV or V pain (89.2%) and were taking 1 or 2 pain medications (74.1%). The median prescription dose was 80 Gy (range 62.5–95 Gy). The proximal trigeminal nerve was targeted in 77.9% of cases, and the median follow-up was 21 months (range 6–156 months). Initial pain relief (modified BNI Pain Intensity Scale grades I–IIIa) was noted in 81.8% of evaluable patients at a median of 30 days. Of 709 patients who achieved initial pain relief, 42.3% experienced at least one pain recurrence after GKRS at a median of 44 months, with 49.0% of these patients undergoing a second procedure. New-onset facial numbness occurred in 25.3% of patients after a median of 8 months. Age ≥ 63 years was associated with a higher probability of both initial pain relief and maintaining pain relief. A distal target location was associated with a higher probability of initial and long-term pain relief, but also a higher incidence of sensory dysfunction. BED ≥ 2100 Gy 2.47 was predictive of pain relief at 30 days and 1 year for the distal target, whereas physical dose ≥ 85 Gy was significant for the proximal target, but the restricted range of BED values in this subgroup could be a confounding factor. A maximum brainstem point dose ≥ 29.5 Gy was associated with a higher probability of bothersome facial numbness.

CONCLUSIONS BED and physical dose were both predictive of pain relief and could be used as treatment planning goals for distal and proximal targets, respectively, while considering maximum brainstem point dose < 29.5 Gy as a potential constraint for bothersome numbness.

Posted on

Radiosurgery With Prior Embolization Versus Radiosurgery Alone for Intracranial Arteriovenous Malformations

Neurosurgery 94:478–496, 2024

The addition of adjuvant embolization to radiosurgery has been proposed as a means of improving treatment outcomes of intracranial arteriovenous malformations (AVMs). However, the relative efficacy and safety of radiosurgery with adjuvant embolization vs radiosurgery alone remain uncertain. Moreover, previous systematic reviews and meta-analyses have included a limited number of studies and did not consider the effects of baseline characteristics, including AVM volume, on the outcomes. This systematic review aimed to evaluate the efficacy of preradiosurgery embolization for intracranial AVMs with consideration to matching status between participants in each treatment group.

METHODS: A systematic review and meta-analysis were conducted by searching electronic databases, including PubMed, Scopus, and Cochrane Library, up to January 2023. All studies evaluating the utilization of preradiosurgery embolization were included.

RESULTS: A total of 70 studies (9 matched and 71 unmatched) with a total of 12 088 patients were included. The mean age of the included patients was 32.41 years, and 48.91% of the patients were female. Preradiosurgery embolization was used for larger AVMs and patients with previous hemorrhage (P < .01, P = .02, respectively). The obliteration rate for preradiosurgery embolization (49.44%) was lower compared with radiosurgery alone (61.42%, odds ratio = 0.56, P < .01), regardless of the matching status of the analyzed studies. Although prior embolization was associated higher rate of cyst formation (P = .04), it lowered the odds of radiation-induced changes (P = .04). The risks of minor and major neurological deficits, postradiosurgery hemorrhage, and mortality were comparable between groups.

CONCLUSION: This study provides evidence that although preradiosurgery embolization is a suitable option to reduce the AVM size for future radiosurgical interventions, it may not be useful for same-sized AVMs eligible for radiosurgery. Utilization of preradiosurgery embolization in suitable lesions for radiosurgery may result in the added cost and burden of an endovascular procedure.

Posted on

Intratumoral Hemorrhage in Vestibular Schwannomas After Stereotactic Radiosurgery: Multi-Institutional Study

Neurosurgery 94:289–296, 2024

Intratumoral hemorrhage (ITH) in vestibular schwannoma (VS) after stereotactic radiosurgery (SRS) is exceedingly rare. The aim of this study was to define its incidence and describe its management and outcomes in this subset of patients.

METHODS: A retrospective multi-institutional study was conducted, screening 9565 patients with VS managed with SRS at 10 centers affiliated with the International Radiosurgery Research Foundation.

RESULTS: A total of 25 patients developed ITH (cumulative incidence of 0.26%) after SRS management, with a median ITH size of 1.2 cm3 . Most of the patients had Koos grade II-IV VS, and the median age was 62 years. After ITH development, 21 patients were observed, 2 had urgent surgical intervention, and 2 were initially observed and had late resection because of delayed hemorrhagic expansion and/or clinical deterioration. The histopathology of the resected tumors showed typical, benign VS histology without sclerosis, along with chronic inflammatory cells and multiple fragments of hemorrhage. At the last follow-up, 17 patients improved and 8 remained clinically stable.

CONCLUSION: ITH after SRS for VS is extremely rare but has various clinical manifestations and severity. The management paradigm should be individualized based on patient-specific factors, rapidity of clinical and/or radiographic progression, ITH expansion, and overall patient condition.

Posted on

Clinical and Imaging Outcomes After Trigeminal Schwannoma Radiosurgery: Results From a Multicenter, International Cohort Study

Neurosurgery 94:165–173, 2024

An international, multicenter, retrospective study was conducted to evaluate the long-term clinical outcomes and tumor control rates after stereotactic radiosurgery (SRS) for trigeminal schwannoma.

METHODS: Patient data (N = 309) were collected from 14 international radiosurgery centers. The median patient age was 50 years (range 11-87 years). Sixty patients (19%) had prior resections. Abnormal facial sensation was the commonest complaint (49%). The anatomic locations were root (N = 40), ganglion (N = 141), or dumbbell type (N = 128). The median tumor volume was 4 cc (range, 0.2-30.1 cc), and median margin dose was 13 Gy (range, 10-20 Gy). Factors associated with tumor control, symptom improvement, and adverse radiation events were assessed.

RESULTS: The median and mean time to last follow-up was 49 and 65 months (range 6–242 months). Greater than 5-year follow-up was available for 139 patients (45%), and 50 patients (16%) had longer than 10-year follow-up. The overall tumor control rate was 94.5%. Tumors regressed in 146 patients (47.2%), remained unchanged in 128 patients (41.4%), and stabilized after initial expansion in 20 patients (6.5%). Progression-free survival rates at 3 years, 5 years, and 10 years were 91%, 86%, and 80 %. Smaller tumor volume (less than 8 cc) was associated with significantly better progression-free survival (P = .02). Seventeen patients with sustained growth underwent further intervention at a median of 27 months (3-144 months). Symptom improvement was noted in 140 patients (45%) at a median of 7 months. In multivariate analysis primary, SRS (P = .003) and smaller tumor volume (P = .01) were associated with better symptom improvement. Adverse radiation events were documented in 29 patients (9%).

CONCLUSION: SRS was associated with long-term freedom (10 year) from additional management in 80% of patients. SRS proved to be a valuable salvage option after resection. When used as a primary management for smaller volume tumors, both clinical improvement and prevention of new deficits were optimized.

Posted on

Vestibular Schwannoma Stereotactic Radiosurgery in Octogenarians

Neurosurgery 93:1099–1105, 2023

The management of octogenarians with vestibular schwannomas (VS) has received little attention. However, with the increase in octogenarian population, more effort is needed to clarify the value of stereotactic radiosurgery (SRS) in this population. The aim of this study was to evaluate the safety and efficacy of SRS in this patient age group.

METHODS: A retrospective study of 62 patients aged 80 years or older who underwent single-session SRS for symptomatic VS during a 35-year interval was performed. The median patient age was 82 years, and 61.3% were male. SRS was performed as planned adjuvant management or for delayed progression after prior partial resection in 5 patients.

RESULTS: SRS resulted in a 5-year tumor control rate of 95.6% with a 4.8% risk of adverse radiation effects (ARE). Tumor control was unrelated to patient age, tumor volume, Koos grade, sex, SRS margin dose, or prior surgical management. Four patients underwent additional management including 1 patient with symptomatic progression requiring surgical resection, 2 patients with symptomatic hydrocephalus requiring cerebrospinal fluid diversion, and 1 patient whose tumor-related cyst required delayed cyst aspiration. Three patients developed ARE, including 1 patient with permanent facial weakness (House-Brackmann grade II), 1 who developed trigeminal neuropathy, and 1 who had worsening gait disorder. Six patients had serviceable hearing preservation before SRS, and 2 maintained serviceable hearing preservation after 4 years. A total of 44 (71%) patients died at an interval ranging from 6 to 244 months after SRS.

CONCLUSION: SRS resulted in tumor and symptom control in most octogenarian patients with VS.

Posted on

Formation of internal carotid artery aneurysms following gamma knife radiosurgery for pituitary adenomas

Acta Neurochirurgica (2023) 165:2257–2265

Only two aneurysm formations in the internal carotid artery after gamma knife radiosurgery (GKRS) for pituitary adenomas are reported so far.

Here, out of the 482 patients who underwent GKRS for pituitary adenomas at our institute, at least five developed aneurysms within the area of high single-dose irradiation. Three patients presented with epistaxis due to aneurysmal rupture and one presented with abducens paralysis due to nerve compression, while one was asymptomatic.

The interval between irradiation and aneurysmal detection ranged from 14 to 21 years. Aneurysm formation in those conditions may be higher than previously thought.

Posted on

Gamma Knife Stereotactic Radiosurgery for Trigeminal Neuralgia Secondary to Multiple Sclerosis

Neurosurgery 93:453–461, 2023

The efficacy of stereotactic radiosurgery (SRS) for the relief of trigeminal neuralgia (TN) is well established. Much less is known, however, about the benefit of SRS for multiple sclerosis (MS)–related TN (MS-TN). OBJECTIVE: To compare outcomes in patients who underwent SRS for MS-TN vs classical/idiopathic TN and identify relative risk factors for failure.

METHODS: We conducted a retrospective, case-control study of patients who underwent Gamma Knife radiosurgery at our center for MS-TN between October 2004 and November 2017. Cases were matched 1:1 to controls using a propensity score predicting MS probability using pretreatment variables. The final cohort consisted of 154 patients (77 cases and 77 controls). Baseline demographics, pain characteristics, and MRI features were collected before treatment. Pain evolution and complications were obtained at follow-up. Outcomes were analyzed using the Kaplan-Meir estimator and Cox regressions.

RESULTS: There was no statistically significant difference between both groups with regards to initial pain relief (modified Barrow National Institute IIIa or less), which was achieved in 77% of patients with MS and 69% of controls. In responders, 78% of patients with MS and 52% of controls eventually had recurrence. Pain recurred earlier in patients with MS (29 months) than in controls (75 months). Complications were similarly distributed in each group and consisted, in the MS group, of 3% of new bothersome facial hypoesthesia and 1% of new dysesthesia.

CONCLUSION: SRS is a safe and effective modality to achieve pain freedom in MS-TN. However, pain relief is significantly less durable than in matched controls without MS.

Proudly powered by WordPress